HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer
JAMA Network Open
•
March 11, 2026
Negative human papillomavirus test predicts low precancer
After a negative human papillomavirus test, long-term risk of treatable cervical precancer stayed very low, and adding cytology offered little extra benefit. *Linked cohort study from trial to registry; Level 2b (OCEBM).
- Level of evidence
- Level 2b (OCEBM)
- DocG quality score
- 6.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
